clinical data
study of HMs
pediatric HMs
clinical decision-making
management of Big Data
patients’ data
HARMONY consortium
efficient sets of HMs outcomes
Big Data sets
Data Quality Supervision Committee
Consortium Management Bodies
improvement of health care of HMs
patient outcomes
clinical decisions
design of innovative clinical
effective management
high-quality HM data repository
key healthcare stakeholders
patient perspective
well-defined management
pre-clinical studies
clinical trials design
Europe-wide data collection
advance innovative concepts of patient management
patient advocacy groups
decision-making structures
heterogeneous HM patient
decision-making procedures
Healthcare Alliance
European institutions
harmonized clinical endpoints
European countries
quality of life
quality criteria
personalized health management processes
policy stakeholders
European study alliances
sets of outcome indicators
comprehensive public-private European consortium of excellence
acute lymphoblastic leukemia
acute myeloid leukemia
Neoplasms
HematologY
Resourceful Medicines Offensive
cooperative groups
regulatory agencies
HTA
Executive Committee
pharmaceutical companies
Steering Committee
Co-operative Working Groups
cross-national healthcare practice
large panel of stakeholders
important key opinion leaders
patients organiza
outcome parameters
outcome measures
key-features
chronic lymphocytic leukemia
pharmaceutical market leaders
innovative accelerated pathways
EFPIA lead companies
novel resources
explorative studies
governance issues
novel drug availability
effective treatment delivery
pan-EU perspective
non-Hodgkin’s lymphoma
benefit profile
long term risk
reimbursement
Associated Members
value analysis
beneficiaries
myelodysplastic syndromes
clear accountabilities
significant recent progress
different sources
differences
disease
multiple myeloma
increasing survival rates
field of hematological malignancies
control of work package
multi-level organizational structure
algorithms
clinicians
appropriate treatments
decision rules
endpoint definitions
leading experts
molecular markers
valid records
review
representatives
unmet medical need
studying
omics
children
platform
activities
framework
General Assembly
participants
specific biomarkers
disorders
adults
partners
experience
complications
WPs
challenges